Ravulizumab: First Global Approval, PMID: 30767127
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study, PMID: 30510079
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study, PMID: 30510080
Ravulizumab, PMID: 31643795
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies, PMID: 30171081
Ravulizumab, PMID: 30694619
Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, PMID: 32011183
The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab, PMID: 33048203
Monitoring Ravulizumab effect on complement assays, PMID: 33321132
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial, PMID: 32660611
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment, PMID: 32299680
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria, PMID: 31534662
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria, PMID: 31949012
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies, PMID: 32449174
Ravulizumab: a complementary option for PNH, PMID: 30733201
Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?, PMID: 32444092
Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome, PMID: 33738756
A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome, PMID: 33001704
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study, PMID: 33178408
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria, PMID: 32886668
No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab, PMID: 32218584
Antibodies to watch in 2019, PMID: 30516432
Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria, PMID: 32519233
Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients, PMID: 32869125
New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab, PMID: 32715723
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment, PMID: 33307104
Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics, PMID: 31703946
Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab, PMID: 32856539
Emerging drugs for the treatment of neuromyelitis optica, PMID: 32731771
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT, PMID: 31258525
Overview of current and emerging therapies for amytrophic lateral sclerosis, PMID: 32840332
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab, PMID: 33301613
Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life, PMID: 34169186
Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis, PMID: 33407224
Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report, PMID: 32803134
Disseminated gonococcal infection in a patient with paroxysmal nocturnal hemoglobinuria having received ravulizumab and meningococcal vaccine, PMID: 32624359
Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019, PMID: 33826106
Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296, PMID: 33276869
Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison, PMID: 34445916
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial, PMID: 32641154
Safety of current treatments for paroxysmal nocturnal hemoglobinuria, PMID: 33249943
Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab, PMID: 33296010
[Antibody therapy for paroxysmal nocturnal hemoglobinuria], PMID: 32908057
Pharmaceutical Approval Update, PMID: 30828229
The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs, PMID: 33512711
Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome, PMID: 33871820
Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome, PMID: 34245447
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs, PMID: 33356783
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults, PMID: 34169200
Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria, PMID: 31916226
For research use only. Not for human or drug use.
